Parth retweeted
Outstanding day for Indian cricket!
Immensely proud of our young cricketers for today’s impressive performance and for winning the Men’s U-19 Asia Cup 2026. Their success will inspire several youngsters.
Best wishes to the team for their endeavours ahead.
𝗖.𝗛.𝗔.𝗠.𝗣.𝗜.𝗢.𝗡.𝗦 🏆
An absolutely incredible run chase in the Final gives India U19 the #MensU19AsiaCup 2026 title 🇮🇳 👏
Scorecard ▶️ bcci.tv/matches/276f2365-6b4…
Parth retweeted
So proud of what @batraatulonc @aiims_newdelhi is doing on so many levels! Terrific public outreach paired with innovative #clinicaltrials. Keep up the amazing work - need to find ways to integrate research with @cityofhope, @SWOG & other groups!
Most cancers are curable when diagnosed early. Know the warning signs, don't ignore symptoms that persist beyond 2–3 weeks, and get screened as advised.
Grateful to @aiims_newdelhi for this #NationalCancerAwarenessDay initiative. #EarlyDetection #CancerAwareness
Parth retweeted
2026 Key European Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice—Commentary Based on a Virtual Focus Group
clinical-breast-cancer.com/a…
Parth retweeted
If/when VOLGA regimen is approved, is this something (3 cycles of EV-Durva) you’d extrapolate for cis eligible MIBC patients as well and use this approach broadly or stick with EV-Pembro (EV304: and push for 9 cycles of EV)? @PGrivasMDPhD @shilpaonc @drenriquegrande @DrKarineTawagi @UroDocAsh @bergsa83 @MikeSerzanMD @BrendanGuercio #ESMO26 @tompowles1 @dr_yakupergun @DrYukselUrun
Parth retweeted
I don’t think people understand just how close we just came to a major, major incident on a cricket field.
Daryl Mitchell seems to be the only one who does.
#NZvIND
Parth retweeted
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!
#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.
• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)
No new safety signals observed.
@myESMO @oncoalert
Parth retweeted
👏👏 looks familiar !
𝑨 𝒎𝒐𝒏𝒖𝒎𝒆𝒏𝒕𝒂𝒍 𝒘𝒊𝒏 🇱🇰
Sri Lanka complete the second-highest chase in Men’s ODI history against England 😲
📝: icc-cricket.com/matches/2741…
Parth retweeted
A game for the ages by @OfficialSLC
Parth retweeted
Replying to @dr_yakupergun @PTarantinoMD
Can’t wait to read through this (while also keeping this editorial by @PTarantinoMD in mind… something that I often share with my patients in helping pick the right treatment in these settings)!
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. Full phase 3 evERA Breast Cancer trial results: nej.md/47ryfbF

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Giredestrant plus Everolimus in Advanced Breast Cancer." The graph shows progression-free survival among patients with ESR1-mutated tumors. The trial name, evERA Breast Cancer, is in parentheses after the title. The NEJM identity sits at the bottom.
Parth retweeted
evERA, by @elmayermd, @stolaney1 et al, is now published in NEJM. Giredestrant outperformed SoC ET when combined with everolimus in HR+/HER2- MBC, particularly in ESR1 mutant disease. Looking forward to having this highly active combo available in clinic. nejm.org/do/10.1056/NEJMdo00…
Parth retweeted
Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. esmoopen.com/article/S2059-7…
Parth retweeted
Here are the treatment algorithms we have used during our DLBCL, FL, and Mantle Cell Lymphoma discussions with @mshadman & @DrJFriedberg
#Lymphoma #OncTwitter #MedTwitter @OncUpdates @OncoAlert
Treatment Algorithm discussion on Diffuse Large B-Cell lymphoma (DLBCL) with @mshadman
✅ Upfront Rx
✅ Sequencing
✅ Side effects/management
Full 🗣️:
⭐️ oncbrothers.com/dlbcl-algo-2…
⭐️ Also on “Oncology Brothers” podcast
#OncTwitter #HemeTwitter @OncUpdates @OncoAlert
Parth retweeted
Today, an @FDA advisory panel voted 7–2, with 1 abstention, that the benefits of @GrailBio Galleri multi-cancer early detection (MCED) test outweigh its risks. A closely watched milestone for the field.
And if you haven’t seen it yet, the NHS-Galleri randomized trial was published yesterday in @NEJM:
nejm.org/doi/abs/10.1056/NEJ…
Parth retweeted
Imlunestrant + Abema now @FDA ✅ based off EMBER-3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ mESR1 advanced BC!
- Imlunestrant alone for mESR1 approved.
- Combo⬆️ mPFS w/all comers (11.1mos vs 5.5mos)
- If co-PIK3CA, Capi or this combo?
#bcsm #OncTwitter @OncUpdates
Oh! The nostalgia!
Aravind Arora was the Zainab Vohra of our times.
A Mumbai based Orthopedician who had a book for almost every subject in the now defunct AIPGMEE. His books ruled the medico bookshelves of 2000s to mid 2010s. Quite strangely, his name never had a face or even his speciality was a guess work them.
I really remember well, his books were top notch. And to know he was an Ortho was truly unbelievable.
1
499
Parth retweeted
Aravind Arora was the Zainab Vohra of our times.
A Mumbai based Orthopedician who had a book for almost every subject in the now defunct AIPGMEE. His books ruled the medico bookshelves of 2000s to mid 2010s. Quite strangely, his name never had a face or even his speciality was a guess work them.
I really remember well, his books were top notch. And to know he was an Ortho was truly unbelievable.









































